retatrutide germany ESC 2024: improves lipid and cardiovascular risk profile in Phase II trial Retatrutide: Premium Research Peptide |
Description
It violates the spirit of sport
The growing number of patients seeking weight loss may eventually lift bariatric procedure volumes, she added
Victoza (liraglutide) [prescribing information]
Common gastrointestinal effects reported with GLP-1 therapy include: Nausea (commonly reported, especially during dose escalation) Constipation or diarrhoea Abdominal discomfort or bloating Reduced appetite and early satiety Regarding bowel movement colour specifically, changes in stool colour are not listed as adverse effects in UK SmPCs for GLP-1 receptor agonists
Maisa Feghali discussed GLP-1 use in women of child-bearing age and the current data available about their use in pregnancy
